Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. European Stop Tyrosine Kinase Inhibitor Trial (euro-ski) In Chronic Myeloid Leukemia: Final Analysis And Novel Prognostic Factors For Treatment-free Remission

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Francois-Xavier Mahon1, Markus Pfirrmann2, Stéphanie Dulucq3,4

  • 1Bergonié Cancer Institute, INSERM UMR1312 Inserm, University of Bordeaux, Bordeaux, France.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 12, 2024

Related Experiment Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

87

View abstract on PubMed

Summary
This summary is machine-generated.

Stopping tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients in deep molecular remission (DMR) is feasible. Treatment duration and BCR::ABL1 transcript type predict maintenance of major molecular response (MMR).

Related Experiment Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

87

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Chronic myeloid leukemia (CML) treatment often involves tyrosine kinase inhibitors (TKIs).
  • Stopping TKIs in patients with stable deep molecular remission (DMR) is an area of active research.
  • The European Stop Kinase Inhibitors (EURO-SKI) study is a large clinical trial investigating TKI cessation in CML.

Purpose of the Study:

  • To evaluate the outcomes of stopping TKIs in patients with CML in stable DMR.
  • To identify factors predicting the maintenance of major molecular response (MMR) after TKI cessation.

Main Methods:

  • The EURO-SKI study enrolled 728 patients with CML in stable DMR.
  • Patients stopped TKIs, and MMR was assessed at 6 and 36 months.
  • Statistical analyses, including multivariate logistic regression, were used to identify predictive factors.

Main Results:

  • At 6 months, 61% of patients remained in MMR; at 36 months, 46% remained in MMR.
  • Duration of TKI treatment and DMR before cessation were significant predictors of MMR loss at 6 months.
  • For late MMR loss and overall MMR maintenance, TKI treatment duration, BCR::ABL1 transcript type, and blast percentage at diagnosis were significant factors.

Conclusions:

  • TKI cessation is a viable strategy for a significant proportion of CML patients in stable DMR.
  • Treatment duration, BCR::ABL1 transcript type, and blast percentage at diagnosis are crucial for predicting treatment-free remission.
  • These factors should guide clinical decisions regarding TKI cessation in CML management.